Meda rejects revised offer from Mylan

by The Associated Press

Swedish pharmaceutical company Meda says it has rejected another offer from U.S. generic drugmaker Mylan Inc.

Meda says its board decided to reject a revised Mylan proposal because the deal lacks support from Meda's largest shareholder, which the did not name in a brief statement. It also says the board turned down the offer due to a strong belief in Meda's potential as a stand-alone company.

Meda says all contact between the companies has ended with no further actions. The Swedish company also rebuffed an approach from Mylan earlier this month.

Mylan representatives did not immediately return a call seeking comment.

Meda's products include the eczema treatment Elidel and the antiseptic Betadine. It says its products are sold in more than 120 countries.

Mylan is based in Canonsburg, Pa.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Indian drugs group eyes $5 bn Swedish deal

May 31, 2013

Indian group Sun Pharmaceutical Industries is in talks to buy leading Swedish drugmaker Meda AB in what could result in a $5 billion takeover, the Wall Street Journal reported on Friday.

US drug firm Mylan to buy Indian firm for $1.6 bn

Feb 27, 2013

US generic drugs specialist Mylan said Thursday it would buy a unit of India's pharma firm Strides Arcolab for $1.6 billion, boosting its presence in the high-growth injectable drugs market.

US drugs firm Mylan completes $1.75 bln India buyout

Dec 05, 2013

US generic drug specialist Mylan said Thursday it had completed its $1.75 billion acquisition of a unit of India's Strides Arcolab, boosting its presence in the high-growth injectable drugs market.

Recommended for you

Use new meningitis vaccines only for outbreaks

8 hours ago

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

12 hours ago

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

Tagging drugs to fight counterfeit medicines

Feb 25, 2015

The U.S. and other countries are enacting rules to clamp down on the sales of fake pharmaceuticals, which pose a public health threat. But figuring out a system to track and authenticate legitimate drugs still faces significant ...

Watchdog group seeks FDA ban of antifungal tablets

Feb 24, 2015

(AP)—A consumer safety group is calling on the Food and Drug Administration to pull certain antifungal tablets off the market, saying there are safer medicines that do not carry risks of liver damage.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.